HCV genotypes

Less Than a Quarter of U.S. Adults Say They’ve Been Tested for Hepatitis C Despite CDC Recommendations for Universal Testing

Retrieved on: 
Tuesday, July 28, 2020
MEN, Health, Insurance, Finance, Consumer, Other Health, Professional services, Philanthropy, Managed care, Infectious diseases, General Health, Foundation, Women, Seniors, Healthcare-associated infections, Health, Medical specialties, Infectious causes of cancer, RTT, Hepatitis C, Hepatitis, Liver disease, Liver, Viral hepatitis, HCV genotypes, Lincoln Financial Group, American Liver Foundation

The same is true when it comes to HCV, the silent epidemic for which theres a cure.

Key Points: 
  • The same is true when it comes to HCV, the silent epidemic for which theres a cure.
  • Unfortunately, the disease has few noticeable symptoms, which often dont appear for years or decades.
  • To learn more about hepatitis C diagnosis, treatment and support, visit HepC123.org
    To see the full hepatitis C survey conducted by Lincoln, click here .
  • Founded in 1976, the American Liver Foundation is the nations largest patient advocacy organization for people living with liver disease.

Enanta’s HCV Collaboration Partner AbbVie Receives Marketing Authorization from European Commission to Shorten MAVIRET® (glecaprevir/pibrentasvir) Duration to Eight Weeks for Treatment-Naïve Genotype 3 HCV Patients with Compensated Cirrhosis

Retrieved on: 
Friday, March 6, 2020
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Chemistry, Chemical compounds, Organic compounds, RTT, Combination drugs, Sulfonamides, Glecaprevir/pibrentasvir, Carbamates, Organofluorides, Cirrhosis, Glecaprevir, HCV genotypes, the EXPEDITION-8 Study2, MAVIRET® (glecaprevir/pibrentasvir), Enanta

The key secondary efficacy endpoints were the percentages of GT1-6 patients achieving SVR12** in a PP and ITT population.

Key Points: 
  • The key secondary efficacy endpoints were the percentages of GT1-6 patients achieving SVR12** in a PP and ITT population.
  • MAVIRET is an 8-week, pan-genotypic (GT 1-6) option for patients without cirrhosis or with compensated cirrhosis and who are new to treatment.
  • * The recommended duration of MAVIRET is 12 weeks in liver or kidney transplant recipients without cirrhosis or with compensated cirrhosis.
  • Glecaprevir/pibrentasvir for 8 weeks in treatment-nave patients with chronic HCV genotypes 16 and compensated cirrhosis: The EXPEDITION-8 trial.

Cepheid Receives CE-IVD clearance for Xpert HCV VL Fingerstick

Retrieved on: 
Wednesday, September 19, 2018
Hepatitis C virus, Healthcare-associated infections, Medicine, HCV genotypes, Hepatitis C, Fingerstick, Clinical medicine

SUNNYVALE, Calif., Sept. 19, 2018 /PRNewswire/ --Cepheid today announced the CE-IVD marking of Xpert HCV VL Fingerstick, the first molecular test to detect and quantify hepatitis C Virus (HCV) RNA levels directly from a fingerstick blood sample.

Key Points: 
  • SUNNYVALE, Calif., Sept. 19, 2018 /PRNewswire/ --Cepheid today announced the CE-IVD marking of Xpert HCV VL Fingerstick, the first molecular test to detect and quantify hepatitis C Virus (HCV) RNA levels directly from a fingerstick blood sample.
  • Cepheid's Xpert HCV VL Fingerstick test allows for a simplified diagnostic pathway.
  • From blood collected into a capillary tube via fingerstick, the simple to use test detects and quantifies a wide range of HCV genotypes within 58 minutes.
  • Evaluation of the Xpert HCV Viral Load Fingerstick point of care assay.

Hepatitis C Infections Resulting From Medical Treatment Occur Despite Clear Guidelines

Retrieved on: 
Tuesday, May 22, 2018
Medicine, Healthcare-associated infections, Infectious causes of cancer, RTT, Immunology, Clinical medicine, Hepatitis C, Hepatitis, Liver disease, HCV genotypes, Infectious diseases within American prisons

Between 2001 and 2011, there were 35 reports of injection safety violations, affecting more than 130,000 patients across 17 states and Washington, DC.

Key Points: 
  • Between 2001 and 2011, there were 35 reports of injection safety violations, affecting more than 130,000 patients across 17 states and Washington, DC.
  • Hepatitis C is a contagious liver disease that is primarily spread through the blood of an infected person or, less commonly, through sexual contact.
  • About 63 percent of HCV infections resulting from medical treatment were discovered only after patients experienced symptoms and were diagnosed, which led to notifying and screening other patients.
  • Edited by Robert Orenstein, DO, it is the premier scholarly peer-reviewed publication of the osteopathic medical profession.